Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Fox Corp Class A (FOXA) Price & Performance

Cytokinetics IncTrade
Fox Corp Class ATrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Fox Corp Class A — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Fox Corp Class A trades at $62.43 (market cap $25.05B). The key difference: Fox Corp Class A is far larger — about 2.3× Cytokinetics Inc's market cap, and Fox Corp Class A pays a 0.91% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKFOXA
Market Cap
$10.78B$25.05B
Sector
TechnologyMedia
52-Week High
$87.26$76.11
52-Week Low
$34.31$48.79
Enterprise Value
$10.88B$28.41B
Dividend Yield
0.91%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.

The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.

Fox Corp Class A

FOXA trades at $64.03, up 3.63% on strong Q4 2026 earnings beats driven by World Cup advertising and Tubi streaming growth. The stock shows bullish technical momentum with a consensus price target of $65.33, supported by a 50% buy rating from analysts. Revenue grew to $16.30B in 2025, with net income margin expanding to 13.88%, though 2026 projections indicate moderation.

Outlook remains positive with digital ad momentum and strategic initiatives, but risks include sports cost pressures and cyclical advertising dependence. The current valuation at a P/E of 16.52 appears reasonable relative to earnings growth, offering potential upside if execution continues.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Fox Corp Class A

Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.

Read more on FOXA